NCT01259102View on ClinicalTrials.gov

Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 30, 2000

Primary Completion Date

March 31, 2001

Study Completion Date

March 31, 2001

Conditions
Healthy
Interventions
DRUG

Buprenorphine transdermal patch

Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.

Trial Locations (1)

43210

The Ohio State University Department of Pharmacology, Columbus

All Listed Sponsors
lead

Purdue Pharma LP

INDUSTRY

NCT01259102 - Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods | Biotech Hunter | Biotech Hunter